Characterization of potential CD138 negative myeloma "stem cells"

Haematologica

Volumn 97, Issue 6, 2012, Pages

  Christensen, Jacob Haaber ^a   Jensen, Pia V ^b   Kristensen, Ida B ^a   Abildgaard, Niels ^a   Lodahl, Marianne ^b   Rasmussen, Thomas ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Annexin V; CD138 negative; Multiple myeloma; Stem cell

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD45 ANTIGEN; CELL SURFACE MARKER; LIPOCORTIN 5; SYNDECAN 1;

APOPTOSIS; BONE MARROW; CLINICAL ARTICLE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER SCANNING CYTOMETRY; LETTER; MYELOMA CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; ARTIFACTS; BONE MARROW CELLS; FLOW CYTOMETRY; HUMANS; LASER SCANNING CYTOMETRY; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; PLASMA CELLS; POLYMERASE CHAIN REACTION; RECURRENCE; RNA, MESSENGER; SPECIMEN HANDLING; SYNDECAN-1; TIME FACTORS;

EID: 84862137226     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.043125     Document Type: Letter

References (9)

1. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332-6.
2. Fuhler GM, Baanstra M, Chesik D, Somasundaram R, Seckinger A, Hose D, et al. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res. 2010;316(11):1816-28.
3. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190-7.
4. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100(4):637-46.
5. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007;109(11):4914-23.
6. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007;282(18):13326-33.
7. Homburg CH, de Haas M, von dem Borne AE, Verhoeven AJ, Reutelingsperger CP, Roos D. Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood. 1995;85(2):532-40.
8. Ihrcke NS, Platt JL. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol. 1996;168(3):625-37.
9. Reiland J, Ott VL, Lebakken CS, Yeaman C, McCarthy J, Rapraeger AC. Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J. 1996;319 (Pt 1):39-47.